[Treatment of erectile dysfunction in patients with plastic induration of the penis].
In selection of patients with erectile dysfunction perspective for conservative treatment we conducted a sialis-test (oral test with tadalafil which is a vasoactive drug, inhibitor of phosphodiesterase of type 5). In sialis negative test we studied a hormonal status of the patient (testosteron level in the blood serum) and performed dopplerography of penile vessels in the course of intracavernous injection of a vasoactive drug. In 2002-2005 we treated 115 patients with erectile dysfunction suffering from plastic induration of the penis. We gave conservative treatment to 66 patients and surgical treatment - to 50 (43%) patients. All surgical patients had evident alterations of penile vessels of cavernous tissue and were not perspective for conservative treatment. Treatment policy in erectile dysfunction in Peyronie's disease is the following: in positive sialis test the patients receive conservative treatment - inhibitors of phosphodiesterase of type 5; in negative sialis test blood hormones (testosteron) should be measured and penile vessels should be studied (dopplerography). In detection of low level of testosteron and normal penile vessels the patients receive combined treatment - replacement hormonal therapy plus inhibitors of phosphodiesterase type 5. In vascular pathology verified at dopplerography and negative tadalafil test the patients receive surgical treatment.
Sokol'shchik
M M
MM
Gagarina
S V
SV
Petrovich
R Iu
RIu
Sadakova
I V
IV
D000328:Adult; D000368:Aged; D000728:Androgens / Q000627:therapeutic use*; D002243:Carbolines / Q000008:administration & dosage*; D007172:Erectile Dysfunction / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D020249:Hormone Replacement Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010411:Penile Induration / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage*; D012189:Retrospective Studies; D000068581:Tadalafil; D013739:Testosterone / Q000097:blood / Q000627:therapeutic use*
D000728:Androgens; D002243:Carbolines; D010726:Phosphodiesterase Inhibitors; D013739:Testosterone; D000068581:Tadalafil